MiR-200b as a prognostic factor in breast cancer targets multiple members of RAB family

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Ye, Feng ^a   Tang, Hailin ^a   Liu, Qing ^b   Xie, Xinhua ^a   Wu, Minqing ^a   Liu, Xiaoping ^a   Chen, Bo ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b The Center for Skull Base Surgery and Neurooncology   (China)

Author keywords

Breast cancer; miR 200b; Prognosis; RAB family

Indexed keywords

MICRORNA 200B; RAB PROTEIN; RAB18 PROTEIN; RAB21 PROTEIN; RAB23 PROTEIN; RAB3B PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER TISSUE; CELL INVASION ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; LUCIFERASE ASSAY; MTT ASSAY; PREDICTION; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN TARGETING; TISSUE MICROARRAY; TUMOR INVASION; WESTERN BLOTTING;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROGNOSIS; RAB GTP-BINDING PROTEINS;

EID: 84892571117     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-17     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636. 10.1200/JCO.2002.02.026, 12202663.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA: the journal of the American Medical Association 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
5. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ. Metastatic Breast Cancer, Version 1.2012 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012, 10:821-829. 3753191, 22773798.
6. Liu H. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci 2012, 69:3587-3599. 10.1007/s00018-012-1128-9, 3513350, 22926415.
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866. 10.1038/nrc1997, 17060945.
8. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA biology 2008, 5:115-119. 10.4161/rna.5.3.6558, 3532896, 19182522.
9. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010, 10:219-222. 10.4161/cbt.10.3.12548, 3040834, 20592490.
10. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, Si J. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009, 44:556-561. 10.1007/s00535-009-0037-7, 19363643.
11. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010, 2010:821717. 2798671, 20049172.
12. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010, 8:1207-1216. 10.1158/1541-7786.MCR-10-0052, 20696752.
13. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601. 10.1038/ncb1722, 18376396.
14. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603. 10.1016/j.cell.2009.07.011, 2731699, 19665978.
15. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011, 18:85-95.
16. Xia W, Li J, Chen L, Huang B, Li S, Yang G, Ding H, Wang F, Liu N, Zhao Q, et al. MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells. Mol Cell Biochem 2010, 344:261-266. 10.1007/s11010-010-0550-2, 20683643.
17. Feng B, Wang R, Chen L-B. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 2012, 66:397-402. 10.1016/j.biopha.2012.06.002, 22795796.
18. Tang H, Wang Z, Liu X, Liu Q, Xu G, Li G, Wu M. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets 2012, 12:1032-1042. 10.2174/156800912803251180, 22834685.
19. Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, Kojima S, Nakagawa M, Seki N. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet 2013, 58:508-516. 10.1038/jhg.2013.31, 23635949.
20. He M, Liu Y, Deng X, Qi S, Sun X, Liu G, Zhao M. Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells. Prostate 2013, 73:1048-1056. 10.1002/pros.22652, 23389960.
21. Cai ZG, Zhang SM, Zhang H, Zhou YY, Wu HB, Xu XP. Aberrant expression of microRNAs involved in epithelial-mesenchymal transition of HT-29 cell line. Cell Biol Int 2013, 37:669-674. 10.1002/cbin.10087, 23483606.
22. Pacurari M, Addison JB, Bondalapati N, Wan YW, Luo D, Qian Y, Castranova V, Ivanov AV, Guo NL. The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol 2013, 43:548-560. 3775564, 23708087.
23. Castilla MA, Diaz-Martin J, Sarrio D, Romero-Perez L, Lopez-Garcia MA, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM, Palacios J. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 2012, 7:e47709. 10.1371/journal.pone.0047709, 3480416, 23112837.
24. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2011, 31:2062-2074. 3330264, 21874049.
25. Yao C-X, Wei Q-X, Zhang Y-Y, Wang W-P, Xue L-X, Yang F, Zhang S-F, Xiong C-J, Li W-Y, Wei Z-R. miR-200b targets GATA-4 during cell growth and differentiation. RNA Biol 2013, 10:0-1.
26. Lim Y-Y, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci 2013, 126:2256-2266. 10.1242/jcs.122275, 23525011.
27. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129. 10.1053/j.gastro.2006.02.057, 16762633.
28. Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 2007, 56:248-253. 10.1016/j.phrs.2007.07.001, 17702597.
29. Jordens I, Marsman M, Kuijl C, Neefjes J. Rab proteins, connecting transport and vesicle fusion. Traffic 2005, 6:1070-1077. 10.1111/j.1600-0854.2005.00336.x, 16262719.
30. Kelly E, Horgan C, Goud B, McCaffrey M. The Rab family of proteins: 25 years on. Biochem Soc Trans 2012, 40:1337-1347. 10.1042/BST20120203, 23176478.
31. Recchi C, Seabra MC. Rab GTPases and their interacting proteins in health and disease: novel functions for Rab GTPases in multiple aspects of tumour progression. Biochem Soc Trans 2012, 40:1398. 10.1042/BST20120199, 3554041, 23176488.
32. Tan PY, Chang CW, Chng KR, Wansa KDSA, Sung W-K, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol 2012, 32:399-414. 10.1128/MCB.05958-11, 3255774, 22083957.
33. Pellinen T, Arjonen A, Vuoriluoto K, Kallio K, Fransen JAM, Ivaska J. Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of beta1-integrins. J Cell Biol 2006, 173:767-780. 10.1083/jcb.200509019, 2063892, 16754960.
34. Eggenschwiler JT, Espinoza E, Anderson KV. Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. Nature 2001, 412:194-198. 10.1038/35084089, 11449277.
35. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V. Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res 2008, 68:4623-4630. 10.1158/0008-5472.CAN-07-5870, 18559507.